Sign in
Not yet taking people in United StatesNo phase

Modulating Inflammation in Neuro-Trauma

Key facts

Who runs it
The University of Texas Health Science Center at San Antonio
Where
San Antonio, United StatesSee the 2 sites
Trial code
Status
Not yet recruiting
People taking part
16 people, planned
Started
Nov 2026
Expected to end
Jul 2027
Type of study
Interventional, 2 groupsOne group gets a sham (pretend) treatment, for comparison.
Treatments tested
  • Nurosym taVNS
  • Nurosym (sham)
Record updated
5 October 2026

Who can take part

Age
18 years to 75 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 15 criteriaShow less

Who can take part

  • Age 18-75 years old
  • Glasgow Coma Scale (GCS) Score 3-12
  • Expected Intensive Care Unit (ICU) stay > 48 hours
  • Presenting with acute Traumatic Brain Injury (TBI) within 24 hours

Who cannot take part

  • Immunomodulatory medication
  • Human Immune Deficiency Virus (HIV) patients
  • Autoimmune disease
  • Known cancer immunotherapy
  • Past medical history of symptomatic bradycardia
  • Pregnant
  • Any electrical implanted device
  • Penetrating brain injury
  • Clinical team assessment of prognosis and imminent risk of death such as Decision to withdraw life-sustaining measures
  • Current incarceration
  • Trauma/Laceration to the left ear

The main criteria, as questions

These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Are you between 18 and 75 years old?

Where in United States

  • University HospitalSan Antonio, United StatesContact: Patrick ThompsonNot yet recruiting
  • University of Texas Health Science Center at San AntonioSan Antonio, United StatesContact: Patrick ThompsonNot yet recruiting

About the trial

What the trial wants to find out

MINT is a single-site, prospective, randomized, double-blind, sham-controlled pilot trial evaluating the safety and feasibility of transcutaneous auricular vagus nerve stimulation (taVNS) in patients with moderate to severe traumatic brain injury (GCS 3-12). Participants will be randomized to receive either active taVNS or sham stimulation using the same device. The primary objective is to assess the safety and feasibility of taVNS implementation in the acute TBI setting. Secondary objectives include exploratory measurement of serum inflammatory and neuronal injury biomarkers and assessment of functional outcome using the Extended Glasgow Outcome Scale at hospital discharge.

The 2 groups in the trial

  • Treatment group taVNSTreatment being tested

    Treatment with transauricular vagus nerve stimulation (taVNS) after admission to trauma with a traumatic brain injury (TBI)

    Treatment: Nurosym taVNS

  • Control groupSham treatment, for comparison

    The control group will undergo sham stimulation using the same device placed at the same location with a brief, low level stimulation that tapers over 30 seconds.

    Treatment: Nurosym (sham)

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
MINT: Modulating Inflammation in Neuro-Trauma
Criteria questions
Built from NCT07510074, who can take part
Record updated
5 October 2026